Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.

Pheochromocytomas and paragangliomas (PPGLs) with pathogenic mutations in the succinate dehydrogenase subunit B (SDHB) are associated with a high metastatic risk. Somatostatin receptor 2 (SSTR2)-dependent imaging is the most sensitive imaging modality for SDHB-related PPGLs, suggesting that SSTR2 expression is a significant cell surface therapeutic biomarker of such tumors. Exploration of the relationship between SSTR2 immunoreactivity and SDHB immunoreactivity, mutational status, and clinical behavior of PPGLs. Evaluation of SSTR-based therapies in metastatic PPGLs. Retrospective analysis of a multicenter cohort of PPGLs at 6 specialized Endocrine Tumor Centers in Germany, The Netherlands, and Switzerland. Patients with PPGLs participating in the ENSAT registry were included. Clinical data were extracted from medical records, and immunohistochemistry (IHC) for SDHB and SSTR2 was performed in patients with available tumor tissue. Immunoreactivity of SSTR2 was investigated using Volante scores. The main outcome measure was the association of SSTR2 IHC positivity with genetic and clinical-pathological features of PPGLs. Of 202 patients with PPGLs, 50% were SSTR2 positive. SSTR2 positivity was significantly associated with SDHB- and SDHx-related PPGLs, with the strongest SSTR2 staining intensity in SDHB-related PPGLs (P = .01). Moreover, SSTR2 expression was significantly associated with metastatic disease independent of SDHB/SDHx mutation status (P < .001). In metastatic PPGLs, the disease control rate with first-line SSTR-based radionuclide therapy was 67% (n = 22, n = 11 SDHx), and with first-line "cold" somatostatin analogs 100% (n = 6, n = 3 SDHx). SSTR2 expression was independently associated with SDHB/SDHx mutations and metastatic disease. We confirm a high disease control rate of somatostatin receptor-based therapies in metastatic PPGLs. © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.

Citation

Alessa Fischer, Simon Kloos, Umberto Maccio, Juliane Friemel, Hanna Remde, Martin Fassnacht, Christina Pamporaki, Graeme Eisenhofer, Henri J L M Timmers, Mercedes Robledo, Stephanie M J Fliedner, Katharina Wang, Julian Maurer, Astrid Reul, Kathrin Zitzmann, Nicole Bechmann, Gintarė Žygienė, Susan Richter, Constanze Hantel, Diana Vetter, Kuno Lehmann, Hermine Mohr, Natalia S Pellegata, Martin Ullrich, Jens Pietzsch, Christian G Ziegler, Stefan R Bornstein, Matthias Kroiss, Martin Reincke, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Svenja Nölting. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses. The Journal of clinical endocrinology and metabolism. 2023 Sep 18;108(10):2676-2685

Mesh Tags

Substances

PMID: 36946182

search → result